GTx forced to stop development of Capesaris (GTx-758)

The US Food & Drug Administration (FDA) has advised GTx to stop development of GTx-758 (also known as Capesaris), its oral drug intended for the treatment of men with advanced prostate cancer, after it became apparent that there was an increase in risk for blood clots in men taking active drug compared to those being [...]

Active surveillance or immediate surgery for low-risk prostate cancer: let’s look at the math

A new study has attempted to calculate the impact of age, health status, and patient preference on the relative outcomes (and merits) of immediate surgery as compared to active surveillance for the management of low-risk prostate cancer.

Elevated cholesterol levels and risk for high-grade prostate cancer

A new report from a Scottish research team offers evidence that high plasma cholesterol levels are associated with an increased risk for a diagnosis of high-grade prostate cancer.

FDA approves Gen-Probe PCA3 test (Progensa)

According to a report today on Xconomy.com, the U.S. Food & Drug Administration has approved the Progensa® PCA3 test developed by Gen-Probe.

How am I meant to get THERE from HERE?

A new report just published on line in the Journal of Urology has shown that — at least in the state of North Carolina — distance from the nearest urologist affects prostate cancer risk category at diagnosis and may disproportionately impact black as opposed to white patients.

Does coronary artery disease increase risk for a diagnosis of prostate cancer?

A study just published on line in Cancer Epidemiology, Biomarkers & Prevention has suggested (albeit not for the first time)  that a baseline history of coronary artery disease may be a meaningful risk factor for prostate cancer.

Can high levels of dietary calcium lower risk for prostate cancer?

Case-control studies based on data from self-reported questionnaires of people’s diets are rarely the most accurate predictors of reality. However, for what it is worth, a new study has reported that higher levels of calcium in a man’s normal diet may be associated with a lower risk for diagnosis of prostate cancer.

Occurrence of infections and hospitalizations in men having prostate biopsy (in Europe)

There has been increased discussion in the past couple of years related to the risk of infection in men undergoing prostate biopsy after initial testing for risk of prostate cancer (based on results of PSA test data and/or a digital rectal examination).

AHRQ responds to letter from Prostate Cancer Roundtable

Members of the Prostate Cancer Roundtable have received a letter from the Agency for Healthcare Research and Quality (AHRQ) addressing issues raised by the Roundtable members about the draft USPSTF recommendations on use of the PSA test in screening for risk of prostate cancer.

The walnuts are back in vogue (at least with mice)

According to a media release we received yesterday, a new paper in the British Journal of Nutrition suggests that “walnuts may help to prevent prostate cancer risk.”

Genomic Health initiates validation study of multi-gene test for prostate cancer

According to a media release issued by Genomic Health on Monday this week, the company has initiated a large clinical validation study of its Oncotype DX® test for prostate cancer.

Mortality rates at 13 years of follow-up in the PLCO study

A new article published on line late Friday in the Journal of the National Cancer Institute shows “no evidence of a mortality benefit for organized annual screening in the PLCO trial compared with opportunistic screening” for prostate cancer.

Prognostic factors for men with primary “signet ring” cancer of the prostate

In January last year we provided summary information about a rare form of prostate cancer known as “signet ring” cancer of the prostate (SRCP). A new report has now added to knowledge about this type of prostate cancer.

Long-term, PSA-based risk for prostate cancer

In September last year we provided information about a Danish study by Orsted et al. on the use of PSA levels in projecting the long-term risk of prostate cancer that had been presented at a scientific meeting in Europe.

The end of EPCA-1 and EPCA-2 as a diagnostic/prognostic test for prostate cancer

According to a news report this morning, a paper originally published in Urology (the Gold Journal) in 2007, and that reported that “early prostate cancer antigen” (EPCA) had the potential to replace the PSA test, has been retracted by the authors.

Follow

Get every new post delivered to your Inbox.

Join 268 other followers